| HOME >> BIOLOGY >> TECHNOLOGY |
In accordance with SFAS No. 123R, the Company estimates total share-based compensation expenses in 2008 will be approximately US$11 million based on employee share options that have been granted as of May 7, 2008. The Company expects approximately US$20 million in acquisition-related intangible amortization expenses in 2008 including the April 2006 acquisition of minority interest and the Datascope acquisition, subject to the finalization of the purchase price allocation for the Datascope acquisition.
The Company expects its capital expenditure for 2008 to be in the range of US$90 million to US$110 million.
The Company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.
The translation rate of RMB to USD in the business outlook section is based on Mindray's estimated average forecast foreign exchange rate, which is RMB6.725 to US$1.00.
Change in Reporting Currency to the U.S. Dollar
Effective April 1, 2008, Mindray changed its reporting currency to the
U.S. Dollar (US$). Mindray will report its consolidated financials in U.S.
Dollars (US$) starting from its second quarter 2008 results. The change in
reporting currency will (1) more accurately reflect Mindray's increased
global operations following the closing of the Datascope acquisition and
(2) improve investors' comprehension of Mindray's financial results and
ability to compare with other companies internationally. Prior to March 31,
2008, the Company's annual and quarterly financial statements and notes
were prepared and reported in Renminbi (RMB). The Company will provide
financial results for periods prior to March 31, 2008, restated to reflect
the US$ as the reporting currency for comparison to the financial results
for the quarters ended March 31, 2007, June 30, 2007, March
'/>"/>
| SOURCE Mindray Medical International Limited Copyright©2008 PR Newswire. All rights reserved |